Welcome to tbtLab!

The Cancer Epigenome research laboratory is focusing on integrated epigenomic and genomic profiling in Asian cancers using enabling technologies such as ChIP-Seq, RNA-seq, Whole-genome and DNA methylation sequencing. The data is then correlated with clinicopathological information including how patients respond to certain drugs. Our research goals are to:

  1. understand the molecular mechanism underlying these cancers;
  2. to identify novel biomarkers than can help determine the nature and behaviour of the disease as well as predicting patients' response to certain drugs; and
  3. to identify novel therapeutic targets with a focus on chromatin enzymes.
The group has hosted and trained clinician scientists, both locally and abroad, who are interested in pursuing translational research. To date, the laboratory has been instrumental in establishing and nurturing several cancer type-based translational research programs at the National Cancer Centre Singapore including biliary tract cancer, lymphoma, sarcoma, breast disease, urological cancer, and peritoneal cancer. The group always emphasizes on collaboration (both local and international) which is key to scientific breakthroughs. The group is now part of the Singapore team that is leading the International Cancer Genome Consortium (ICGC) project on biliary tract cancer. The group is also an integral part of the Lymphoma TCR (Translational Clinical Research) Program.

Professor Bin Tean TEH

Director, SingHealth Duke-NUS Institute of Biodiversity Medicine (BD-MED)
Deputy Chief Executive Officer (Research), National Cancer Centre Singapore
Deputy Director (Global Relations), SingHealth Duke-NUS Institute of Precision Medicine
Professor, Duke-NUS Medical School, Singapore
Senior Principal Investigator, Institute of Molecular and Cell Biology, Singapore
Senior Group Leader, Genome Institute of Singapore